Drug Profile
Dorzolamide/latanoprost
Alternative Names: ALZ-1101Latest Information Update: 12 Feb 2016
Price :
$50
*
At a glance
- Originator Alleanza Pharmaceuticals
- Class Antiglaucomas; Antihypertensives; Eye disorder therapies; Prostaglandins; Small molecules; Sulfonamides; Thiophenes
- Mechanism of Action Carbonic anhydrase inhibitors; Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glaucoma; Ocular hypertension
Most Recent Events
- 11 Feb 2016 No recent reports on development identified - Phase-II for Glaucoma in USA (Ophthalmic)
- 11 Feb 2016 No recent reports on development identified - Phase-II for Ocular hypertension in USA (Ophthalmic)
- 01 Jan 2014 Alleanza Pharmaceuticals completes a phase II trial in Glaucoma and Ocular hypertension in USA (NCT01896180)